The present study examines the influence of kinins on the migratory capacity of human polymorphonuclear leukocytes under in vitro conditions using the Boyden chamber technique. By means of checkerboard analysis the migration of neutrophils induced by bradykinin could be characterized as true chemotaxis. The stimulation of human neutrophils with bradykinin, with the nonpeptide B2 receptor agonist FR190997 as well as with des-Arg9-bradykinin and des-Arg10-kallidin results in a concentration-dependent migration. Pretreatment of the neutrophils with the B2 receptor antagonist HOE-140 (icatibant) inhibited the bradykinin-induced migration but not that induced by B1 receptor agonists, whereas the B1 receptor antagonist des-Arg10HOE-140 abolished the migration elicited by des-Arg9-bradykinin or des-Arg10-kallidin but not that evoked by bradykinin. Pretreatment of the neutrophils with the leukotriene B4 (LTB4) antagonist ZK158252 inhibited the LTB4-induced chemotaxis as well as the chemotaxis produced by bradykinin and des-Arg10-kallidin. An involvement of interleukin-1β and of the chemokine IL-8 in the bradykinin-induced migration in vitro could be excluded during the migration time of the neutrophils. In conclusion, the present study provides pharmacological evidence showing that B1 and B2 kinin receptors are involved in the migration of human neutrophils in vitro, that LTB4 participates in the downstream pathway and that the B1 kinin receptor seems to be expressed already under physiological conditions.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.